title: Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host.
abstract: Brincidofovir (BCV) is a broad-spectrum antiviral agent active in vitro against double-stranded DNA viruses including herpesviruses, adenoviruses, polyomaviruses, and poxviruses. We report successful BCV use in management of disseminated acyclovir- and cidofovir-resistant varicella zoster virus in an immunocompromised hematopoietic stem cell transplant patient with chronic graft-versus-host disease who was intolerant to foscarnet.
authors.affiliation: Medicine, University of Chicago, Chicago, Illinois, USA. kmullane@medicine.bsd.uchicago.edu.
authors.forename: K M
authors.initials: KM
authors.lastname: Mullane
authors.affiliation: Medicine, University of Chicago, Chicago, Illinois, USA.
authors.forename: C
authors.initials: C
authors.lastname: Nuss
authors.affiliation: Medicine, University of Chicago, Chicago, Illinois, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ridgeway
authors.affiliation: Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: M N
authors.initials: MN
authors.lastname: Prichard
authors.affiliation: Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: C B
authors.initials: CB
authors.lastname: Hartline
authors.affiliation: Medicine, University of Chicago, Chicago, Illinois, USA.
authors.forename: J
authors.initials: J
authors.lastname: Theusch
authors.affiliation: Chimerix, Inc., Durham, North Carolina, USA.
authors.forename: H
authors.initials: H
authors.lastname: Mommeja-Marin
authors.affiliation: Medicine, University of Chicago, Chicago, Illinois, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Larson
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000097:blood / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006562:Herpes Zoster / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D014645:Herpesvirus 3, Human / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D016867:Immunocompromised Host; D017387:Investigational New Drug Application; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000009:adverse effects; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D015507:Drugs, Investigational; D063065:Organophosphonates; D017245:Foscarnet; C525733:brincidofovir; D003596:Cytosine; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir
keywords: acyclovir-resistant; brincidofovir; disseminated varicella